Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study

Background: Infection by SARS-CoV-2 has unquestionably had an impact on the health of patients with chronic respiratory airway diseases, such as COPD and asthma, but little information is available about its impact on patients with bronchiectasis. The objective of the present study was to analyze the effect of the SARS-CoV-2 pandemic on the state of health, characteristics, and clinical severity (including the number and severity of exacerbations) of patients with non-cystic fibrosis bronchiectasis. Methods: This study was multicenter, observational, and ambispective (with data collected before and during the SARS-CoV-2 pandemic), and included 150 patients diagnosed with non-cystic fibrosis bronchiectasis. Results: A significant drop was observed in the number and severity of the exacerbations (57% in all exacerbations and 50% in severe exacerbations) in the E-FACED and BSI multidimensional scores, in the pandemic, compared with the pre-pandemic period. There was also a drop in the percentage of sputum samples positive for pathogenic microorganisms in general (from 58% to 44.7%) and, more specifically, Pseudomonas aeruginosa (from 23.3% to 13.3%) and Haemophilus influenzae (from 21.3% to 14%). Conclusions: During the SARS-CoV-2 period, a significant reduction was observed in the exacerbations, severity, and isolations of pathogenic microorganisms in patients with bronchiectasis.

[1]  C. Chen,et al.  Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review , 2022, The Journal of infectious diseases.

[2]  K. Laurie,et al.  Influenza lineage extinction during the COVID-19 pandemic? , 2021, Nature Reviews Microbiology.

[3]  T. Welte,et al.  Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. , 2021, The Lancet. Respiratory medicine.

[4]  T. Zewotir,et al.  Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients , 2021, BMC Infectious Diseases.

[5]  M. Miravitlles,et al.  Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis , 2021, PloS one.

[6]  I. König,et al.  Effect of comorbid pulmonary disease on the severity of COVID‐19: A systematic review and meta‐analysis , 2021, Respirology.

[7]  J. Riera,et al.  [CIBERESUCICOVID: A strategic project for a better understanding and clinical management of COVID-19 in critical patients]. , 2021, Archivos de bronconeumologia.

[8]  A. Shoemark,et al.  The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study , 2021, American journal of respiratory and critical care medicine.

[9]  A. Tiotiu.  Impact of COVID-19 on the most frequent middle and lower obstructive airway diseases/syndromes in adult population , 2021, Archivos de Bronconeumología.

[10]  J. L. López-Campos,et al.  Escalas pronósticas de morbimortalidad por COVID-19: necesarias pero también fiables , 2021, Archivos de Bronconeumología.

[11]  D. Halpin,et al.  COPD & COVID-19 , 2021, Archivos de Bronconeumología.

[12]  L. Wee,et al.  COVID-19 public health measures: a reduction in hospital admissions for COPD exacerbations , 2020, Thorax.

[13]  J. Riera,et al.  CIBERESUCICOVID: A strategic project for a better understanding and clinical management of COVID-19 in critical patients. , 2020, Archivos de bronconeumologia.

[14]  F. Barbé,et al.  CIBERESUCICOVID: un proyecto estratégico para una mejor comprensión y manejo clínico de la COVID-19 en pacientes críticos , 2020, Archivos de Bronconeumología.

[15]  D. Ferri,et al.  The spectrum of COVID-19 disease in adolescents , 2020, Archivos de Bronconeumología.

[16]  F. Martín-Sánchez,et al.  Management and follow up of respiratory patients in the post-Covid-19 era: Are we ready yet? , 2020, Archivos de Bronconeumología (English Edition).

[17]  R. López-Reyes,et al.  Riesgo trombótico y COVID-19: revisión de la evidencia actual para una mejor aproximación diagnóstica y terapéutica , 2020, Archivos de Bronconeumología.

[18]  J. Mayol,et al.  Lung cancer patients on the waiting list in the midst of the COVID-19 crisis: what do we do now? , 2020, Archivos de Bronconeumología (English Edition).

[19]  R. Chavasse,et al.  The Indirect Impact of COVID-19 on Children With Asthma , 2020, Archivos de Bronconeumología.

[20]  Eva Tabernero Huguet,et al.  Alteración funcional pulmonar en el seguimiento precoz de pacientes con neumonía por COVID-19 , 2020, Archivos de Bronconeumología.

[21]  X. Castells,et al.  Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain , 2020, Archivos de Bronconeumología.

[22]  Rosa Cordovilla Pérez,et al.  Impacto de la pandemia COVID-19 en los laboratorios de función pulmonar: consideraciones sobre el «hoy» y el «día después» , 2020, Archivos de Bronconeumología.

[23]  F. Burgos Rincón,et al.  Impact of the COVID-19 Pandemic on Lung Function Laboratories: Considerations for "Today" and the "Day After". , 2020, Archivos de bronconeumologia.

[24]  M. García-Pais,et al.  Factores asociados al ingreso hospitalario en un protocolo asistencial en COVID-19 , 2020, Archivos de Bronconeumología.

[25]  R. Golpe,et al.  Factors Associated to Hospital Admission in a Care Protocol in COVID-19 , 2020, Archivos de Bronconeumología (English Edition).

[26]  M. Martínez-García,et al.  Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. , 2020, Archivos de bronconeumologia.

[27]  A. Abalkhail,et al.  Prevalence and mortality of lung comorbidities among patients with COVID-19: A systematic review and meta-analysis , 2020, medRxiv.

[28]  J. L. Izquierdo Alonso,et al.  La neumología en tiempos de COVID-19 , 2020, Archivos de Bronconeumología.

[29]  Jesús Molina París,et al.  Seguimiento del paciente con enfermedad respiratoria en la era post-COVID-19: ¿estamos preparados? , 2020, Archivos de Bronconeumología.

[30]  Bernardino Alcázar Navarrete,et al.  Pacientes con carcinoma broncogénico en lista de espera en plena crisis del COVID-19: ¿y ahora qué hacemos? , 2020, Archivos de Bronconeumología.

[31]  C. Olveira,et al.  Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  W. Guan,et al.  The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study , 2020, Archivos de Bronconeumología.

[33]  C. Olveira,et al.  CAT (COPD ASSESSMENT TEST) In Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation. A Prospective Study. , 2020, Chest.

[34]  J. Ludvigsson.  Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults , 2020, Acta paediatrica.

[35]  Dae-Gyun Ahn,et al.  Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) , 2020, Journal of microbiology and biotechnology.

[36]  G. Olveira,et al.  Validity of Self-rating Screening Scales for the Diagnosis of Depression and Anxiety in Adult Patients With Bronchiectasis. , 2020, Archivos de bronconeumologia.

[37]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[38]  C. Olveira,et al.  RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients. , 2020, Archivos de bronconeumologia.

[39]  E. Monso,et al.  Look at the wood and not at the tree: The Microbiome in Chronic Osxtructive Lung Disease and Cystic Fibrosis. , 2020, Archivos de bronconeumologia.

[40]  C. Olveira,et al.  Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. , 2019, Archivos de bronconeumologia.

[41]  M. Martínez-García.  Pseudomonas aeruginosa infection and exacerbations in bronchiectasis: more questions than answers , 2018, European Respiratory Journal.

[42]  C. Olveira,et al.  The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis , 2018, ERJ Open Research.

[43]  C. Olveira,et al.  Spanish Guidelines on Treatment of Bronchiectasis in Adults. , 2017, Archivos de bronconeumologia.

[44]  T. Welte,et al.  Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research , 2017, European Respiratory Journal.

[45]  J. Laffey,et al.  Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. , 2016, The Lancet. Respiratory medicine.

[46]  J. Laffey,et al.  Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts , 2016, Thorax.

[47]  J. Elborn,et al.  Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. , 2016, Respiratory medicine.

[48]  E. Klein,et al.  The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysis , 2016, Influenza and other respiratory viruses.

[49]  C. Olveira,et al.  Annual direct medical costs of bronchiectasis treatment , 2016, Chronic respiratory disease.

[50]  G. Sotgiu,et al.  Clinical phenotypes in adult patients with bronchiectasis , 2016, European Respiratory Journal.

[51]  J. Chalmers,et al.  A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. , 2015, Annals of the American Thoracic Society.

[52]  W. Guan,et al.  The Role of Viral Infection in Pulmonary Exacerbations of Bronchiectasis in Adults , 2015, Chest.

[53]  G. Olveira,et al.  Mediterranean diet is associated on symptoms of depression and anxiety in patients with bronchiectasis. , 2014, General hospital psychiatry.

[54]  C. Olveira,et al.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score , 2012, European Respiratory Journal.

[55]  A. Hill,et al.  Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis , 2009, European Respiratory Journal.

[56]  G. Aughenbaugh,et al.  High-Resolution CT of the Lung, 3rd ed. , 2001 .

[57]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[58]  David P. Naidich,et al.  High-Resolution CT of the Lung , 1997 .

[59]  R. Gleckman,et al.  Sputum gram stain assessment in community-acquired bacteremic pneumonia , 1988, Journal of clinical microbiology.

[60]  OUP accepted manuscript , 2022, The Journal of Infectious Diseases.

[61]  E. Monso.  Look at the wood and not at the tree: The microbiome in chronic obstructive lung disease and cystic fibrosis , 2020 .

[62]  C. Hernández,et al.  [Pulmonary function and quality of life in relation to bronchial colonization in adults with bronchiectasis not caused by cystic fibrosis]. , 2002, Medicina clinica.

[63]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.